Drug Trial Radar · NCT02576431
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
215
Actual
Start
Sep 30, 2015
Primary completion
Sep 29, 2025
Study completion Sep 29, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
Conditions
- Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)Drug
Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best overall response of confirmed complete response (CR) or partial response (PR) as determined by an independent radiology review committee using RECIST v1.1 or RANO criteria, as appropriate to tumor type.Time frame: Up to 120 months
Locations
98 sites in 25 countries. Site status is shown where the registry gives one.
Stanford Cancer Center Palo Alto
Palo Alto, California
UCLA Health Santa Monica Cancer Care
Santa Monica, California
Memorial Cancer Institute at West
Pembroke Pines, Florida
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology
Chicago, Illinois
Mass General Cancer Center
Boston, Massachusetts
Dana-Farber Cancer Institute - Oncology Department
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York
UNC Hospitals - UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
Cleveland Clinic - Neurology
Cleveland, Ohio
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Avera Cancer Institute - Sioux Falls
Sioux Falls, South Dakota
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas
Inova Schar Cancer Institute
Fairfax, Virginia
Fred Hutch Cancer Center - Sloan Clinic 1
Seattle, Washington
West Virginia University
Morgantown, West Virginia
Hospital Alemán
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno"
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Fundación Cenit para la Investigación en Neurociencias
CABA, Ciudad Auton. de Buenos Aires, Argentina
Centro Medico Austral
TBC, Ciudad Auton. de Buenos Aires, Argentina
Centro Médico San Roque
San Miguel de Tucumán, Tucumán Province, Argentina
Macquarie University Hospital
Sydney, New South Wales, Australia
Royal Darwin Hospital
Tiwi, Northern Territory, Australia
St John of God Healthcare
Subiaco, Western Australia, Australia
Institut Jules Bordet/Jules Bordet Instituut
Brussels, Belgium
Hosp. Araujo Jorge da Associação de Combate ao Câncer
Goiânia, Goiás, Brazil
Cenantron Centro Avançado de Tratamento Oncológico, Ltda.
Belo Horizonte, Minas Gerais, Brazil
Instituto Nacional do Câncer - INCA - HC II
Rio de Janeiro, Rio de Janeiro, Brazil
INCA - Hospital do Cancer III
Rio de Janeiro, Rio de Janeiro, Brazil
Oncoclínicas Rio de Janeiro S.A
Rio de Janeiro, Rio de Janeiro, Brazil
Fundacao Pio XII - Hospital de Cancer de Barretos
Barretos/SP, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo
São Paulo, São Paulo, Brazil
Real e Benemérita Associação Portuguesa de Beneficência
São Paulo, São Paulo, Brazil
Hospital Sirio Libanes
São Paulo, São Paulo, Brazil
IBCC - Instituto Brasileiro de Controle do Cancer
São Paulo, São Paulo, Brazil
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Zhongshan Hospital, Fudan University - Oncology Department
Shanghai, China
Beijing Cancer Hospital - Oncology Department
Beijing, Beijing Municipality, China
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.